Dyadic International Inc - Asset Resilience Ratio

Latest as of September 2025: 26.55%

Dyadic International Inc (DYAI) has an Asset Resilience Ratio of 26.55% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Dyadic International Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$3.10 Million
Cash + Short-term Investments

Total Assets

$11.67 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2024)

This chart shows how Dyadic International Inc's Asset Resilience Ratio has changed over time. See Dyadic International Inc (DYAI) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Dyadic International Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DYAI stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $3.10 Million 26.55%
Total Liquid Assets $3.10 Million 26.55%

Asset Resilience Insights

  • Very High Liquidity: Dyadic International Inc maintains exceptional liquid asset reserves at 26.55% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Dyadic International Inc Industry Peers by Asset Resilience Ratio

Compare Dyadic International Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Dyadic International Inc (2005–2024)

The table below shows the annual Asset Resilience Ratio data for Dyadic International Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 27.76% $2.76 Million $9.93 Million +18.66pp
2023-12-31 9.10% $748.29K $8.22 Million -40.83pp
2022-12-31 49.93% $6.85 Million $13.71 Million +28.75pp
2021-12-31 21.18% $4.51 Million $21.30 Million -6.94pp
2020-12-31 28.12% $8.46 Million $30.07 Million -50.37pp
2019-12-31 78.50% $29.40 Million $37.45 Million -11.15pp
2018-12-31 89.64% $38.82 Million $43.30 Million +7.08pp
2017-12-31 82.57% $41.90 Million $50.74 Million +10.93pp
2016-12-31 71.64% $42.05 Million $58.70 Million +70.21pp
2014-12-31 1.43% $122.00K $8.54 Million +0.09pp
2013-12-31 1.34% $200.00K $14.94 Million -0.15pp
2012-12-31 1.49% $192.00K $12.88 Million -0.59pp
2011-12-31 2.08% $214.00K $10.30 Million -0.34pp
2010-12-31 2.41% $247.00K $10.23 Million +0.21pp
2009-12-31 2.20% $316.00K $14.36 Million -1.10pp
2008-12-31 3.30% $344.00K $10.43 Million +1.96pp
2007-12-31 1.34% $349.00K $26.09 Million +1.19pp
2005-12-31 0.15% $35.00K $23.75 Million --
pp = percentage points

About Dyadic International Inc

NASDAQ:DYAI USA Biotechnology
Market Cap
$30.71 Million
Market Cap Rank
#23740 Global
#5080 in USA
Share Price
$0.85
Change (1 day)
+8.91%
52-Week Range
$0.68 - $1.30
All Time High
$10.26
About

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and la… Read more